Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (pts) with metastatic urothelial cancer (mUC) Meeting Abstract
| Authors: | Rosenberg, J. E.; Heath, E.; Perez, R.; Merchan, J.; Lang, J.; Ruether, D.; Petrylak, D.; Sangha, R.; Smith, D. C.; Sridhar, S.; Gartner, E.; Vincent, M.; Chu, R.; Anand, B.; Donate, F.; Melhem-Bertrandt, A.; Zhang, J. |
| Abstract Title: | Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (pts) with metastatic urothelial cancer (mUC) |
| Meeting Title: | 41st European Society for Medical Oncology Congress (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 27 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Oct 7-11 |
| Meeting Location: | Copenhagen, Denmark |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-10-01 |
| Start Page: | vi273 |
| Language: | English |
| ACCESSION: | WOS:000393912500784 |
| DOI: | 10.1093/annonc/mdw373.16 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 788P -- Source: Wos |
